To Evaluate the Efficacy and Safety of Cross-linked Hyaluronic Acid Filler for Injection in the Correction of Moderate to Severe Nasolabial Wrinkles: A Multicenter Randomized Clinical Study
In brief
Cross-linked hyaluronic acid filler was effective in over 95% through six months
In an 88-person split-face trial, the filler had investigator- and patient-rated effective rates above 95% at one, three and six months, and was non-inferior to a marketed comparator. No treatment-related serious adverse events occurred; reported reactions were mild and resolved without treatment. The study supports short-term efficacy, but longer-term durability remains less clear.
- Journal
- Aesthetic plastic surgery (Q1)
- Published
- 12 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Weirong Shi, Yanan Xue, Wei Feng, Yao Wu, Feifei Guo, Yingjie Wang, et al.
- PMID
- 43020919
- DOI
- 10.1007/s00266-026-06409-7
Why clinicians should know about it
- Picked for Plastic and Reconstructive Surgery (top studies of the week, 15 November 2026): Randomized comparative evidence for facial aesthetic filler
Abstract
OBJECTIVE: To evaluate the safety and efficacy of a cross-linked hyaluronic acid filler for facial aesthetic applications in clinical practice. METHODS: A randomized, single-blind, self-controlled (split-face) non-inferiority trial was conducted at two investigational sites. A total of 88 subjects were enrolled, with each subject receiving the test product on one nasolabial fold and the marketed comparator on the contralateral side, resulting in 88 treated sides per group. The injection volume was determined according to the Wrinkle Severity Rating Scale (WSRS) grade of each fold, and all injections were administered into the deep dermis. Efficacy of the dermal injection treatment was assessed by both investigators and subjects using WSRS scores at baseline and at 1, 3 and 6 months post-treatment. Long-term safety and durability were evaluated through a 12-month follow-up. Safety monitoring included demographic data, vital signs, laboratory tests, telephone interviews and subject diary cards throughout the study period. Statistical analysis was performed using conservative independent-sample tests for the primary efficacy comparison, with non-inferiority assessed via the 95% confidence interval for the rate difference. RESULTS: All 88 subjects completed the scheduled evaluations. The overall effective rate for the test product exceeded 95% at all time points. Investigator-assessed effective rates were 97.73% at Month 1, 95.45% at Month 3 and 95.45% at Month 6. Subject-assessed effective rates were 96.59%, 97.73% and 96.59% at the corresponding time points. The consistency rate between investigator and subject evaluations was above 95% across all visits. No treatment-related serious adverse events were observed; reported adverse reactions were mild, transient and resolved without intervention. CONCLUSION: Based on clinical observation, the cross-linked hyaluronic acid filler evaluated in this study demonstrated satisfactory safety and efficacy, with performance non-inferior to that of the marketed comparator. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.